The China Paradox in LEAP-012 Trial

Masatoshi Kudo · 2026

Read The China Paradox in LEAP-012 Trial by Masatoshi Kudo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13241163.txt.

Description

Masatoshi Kudo probes a China paradox in the LEAP-012 liver cancer trial in a 2026 commentary. For decades, arterial chemoembolization anchored care for intermediate-stage liver tumors, until immune and vessel-blocking drugs reshaped the field.

The trial added two such drugs to the artery procedure and clearly lengthened the time before tumors progressed, from ten months to about fourteen and a half. Yet benefit looked far larger in Chinese patients than in the global pool. Kudo asks whether the regimen truly works better in China, or whether the control arm's artery procedure simply performed worse there. The answer matters for reading every ongoing trial of this kind, he argues.

Catalog record

CREATORMasatoshi Kudo
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE15 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13241163

Browse the full library · About the Tower of Babel